Abacavir hydroxyacetate
Antiretroviral combination therapy for HIV-1 infection
- CAS No.
- 1446418-48-9
- Indication Class
- Anti-infectives
- Patent Expiry
- Off-patent · 2012
- Therapeutic Area
- Anti-infective / HIV
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- Candidate (In-research)
- Linked Intermediates
- Confirm per inquiry
- Patent Scope
- Compound patent long expired; mature multi-source generic supply
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A classic nucleoside reverse-transcriptase inhibitor still anchoring AIDS cocktail therapy; long-term must-have in national public-health procurement.
Anti-infective / HIV · In research; suited to co-development
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Abacavir hydroxyacetate is a salt form of Abacavir, which blocks viral replication by inhibiting the reverse transcriptase of the Human immunodeficiency virus and is used in the treatment and research of HIV/AIDS.
Supply source: Unibest · Abacavir hydroxyacetate, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.